Washington Monument

After exploring a mechanistic approach and a tumour type as part of our AACR annual meeting coverage, in our third preview today we turn to look at a novel target.

This particular target hasn’t received much attention at all but this could well change in the future as some of the compounds move into the clinic.

There are a few important questions to consider:

  • Who’s going to be first to evaluate in humans?
  • Which tumour types will be optimal?
  • Which combinations are likely to be synergistic, tolerable and effective?
  • What path to market strategies will avoid the enrollment problems now that checkpoint blockade is becoming much more ubiquitous?

This is an interesting niche that may well evolve into a competitive landscape going forward.

Subscribers can log-in below or you can sign up via the blue box to learn more about our insights…

Posted by 

Purchase Access to Premium Content

PLEASE READ BEFORE YOU BUY. Click on blue icon to purchase a PERSONAL, INDIVIDUAL license to premium content. Please READ our TERMS OF USE before purchasing (link at bottom of page): You are NOT PERMITTED to share access or copies of posts. If you work for a CONSULTING FIRM, AGENCY, or are in PR, COMMUNICATIONS OR MEDIA (that includes JOURNALISTs & WRITERs), you cannot purchase an INDIVIDUAL license through this site without prior approval (even if your use is personal) and typically a CORPORATE license will be required. Please CONTACT US to discuss how you might use our content & obtain a quote for the appropriate license. Rates may change without notice and are non-refundable. If you in any doubt about whether you can buy through the blue icon, PLEASE CONTACT US first.